Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Akshanth R. Polepally, PhD, Monica Motwani, PhD, Yunming Mu, PhD, Zeena Salman, MPH, Sudhir Penugonda, MD MPH, Philippe Moreau, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137037

Published: 2020

Journal Articles

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE TM Study

Christian Buske, MD, Alessandra Tedeschi, MD, Judith Trotman, FRACP, Ramon García-Sanz, MD PhD, David MacDonald, MD, Véronique Leblond, MD PhD, Beatrice Mahe, MD, Charles Herbaux, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, M. Lia Palomba, MD, Jeffrey V Matous, MD, Chaim Shustik, MD, Eftathios Kastritis, MD, Steven P Treon, MD PhD FRCP, Chih-Jian Lih, PhD, Jianling Li, MS, Zeena Salman, BS, Thorsten Graef, MD PhD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 149.

https://doi.org/10.1182/blood-2018-99-111178

Published: 2018

Journal Articles

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, Saulius Girnius, MD, Saurabh Chhabra, MD, Robert Frank Cornell, MD, Cristina J. Gasparetto, MD, Chatchada Karanes, MD, Matthew A. Lunning, DO, Jeffrey V. Matous, MD, Ruben Niesvizky, MD, Chaim Shustik, MD, Robert K. Stuart, MD, Jason Lih, PhD, Yihua Lee, PhD, Zeena Salman, Thorsten Graef, MD PhD, Jason Valent, MD

Blood (2017) 130 (Supplement 1): 3111.

https://doi.org/10.1182/blood.V130.Suppl_1.3111.3111

Published: 2017

Journal Articles

A Novel Three-Dimensional Co-Culture System to Study Leukemia in the Bone Marrow Microenvironment

Zeena Salman, MD MPH, Juan Carlos Balandrán-Juárez, Rosana Pelayo, PhD, Monica L. Guzman, PhD

Blood (2015) 126 (23): 1864.

https://doi.org/10.1182/blood.V126.23.1864.1864

Published: 2015

Journal Articles

In Vivo Treatment with TG-02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents

Zeena Salman, MD MPH, Jeanne P. De Leon, Eric J. Feldman, MD, Francis Burrows, PhD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2014) 124 (21): 3765.

https://doi.org/10.1182/blood.V124.21.3765.3765

Published: 2014

Journal Articles

Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

Jennifer R Brown, MD, PhD, Jaqueline C. Barrientos, MD, Paul M. Barr, MD, Ian Flinn, MD, PhD, Jan A. Burger, MD, PhD, Zeena Salman, Fong Clow, ScD, Danelle F. James, MD, Thorsten Graef, MD, PhD, Jonathan W. Friedberg, MD, Kanti R. Rai, M.D., Susan O'Brien, MD

Blood (2013) 122 (21): 525.

https://doi.org/10.1182/blood.V122.21.525.525

Published: 2013

NARROW

A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE TM Study

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

A Novel Three-Dimensional Co-Culture System to Study Leukemia in the Bone Marrow Microenvironment

In Vivo Treatment with TG-02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents

Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

Email alerts

ASH Publications

American Society of Hematology

A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE TM Study

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

A Novel Three-Dimensional Co-Culture System to Study Leukemia in the Bone Marrow Microenvironment

In Vivo Treatment with TG-02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents

Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only